CD274 and neoplasm: In a post hoc analysis, the DFS benefit was seen in tumours with a PD-L1 combined positive score (CPS) of <5 as well as ≥5, with a hazard ratio of (0.62 [95% CI 0.46–0.83] vs. 0.89 [0.65–1.22]) respectively [47].